Baird Financial Group Inc. Trims Holdings in Astera Labs, Inc. $ALAB

Baird Financial Group Inc. trimmed its position in Astera Labs, Inc. (NASDAQ:ALAB - Free Report) by 90.4% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,500 shares of the company's stock after selling 42,515 shares during the period. Baird Financial Group Inc.'s holdings in Astera Labs were worth $269,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Astera Labs by 2,824.4% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 154,524 shares of the company's stock worth $20,467,000 after acquiring an additional 149,240 shares during the period. Aigen Investment Management LP increased its position in Astera Labs by 50.9% during the 1st quarter. Aigen Investment Management LP now owns 17,920 shares of the company's stock worth $1,069,000 after purchasing an additional 6,045 shares in the last quarter. Pacific Point Advisors LLC increased its position in Astera Labs by 75.0% during the 1st quarter. Pacific Point Advisors LLC now owns 7,000 shares of the company's stock worth $418,000 after purchasing an additional 3,000 shares in the last quarter. Oppenheimer Asset Management Inc. increased its position in Astera Labs by 73.6% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 15,995 shares of the company's stock worth $954,000 after purchasing an additional 6,783 shares in the last quarter. Finally, Taylor Frigon Capital Management LLC acquired a new stake in Astera Labs during the 1st quarter worth approximately $1,887,000. 60.47% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Astera Labs

In other Astera Labs news, COO Sanjay Gajendra sold 91,441 shares of the business's stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $183.51, for a total value of $16,780,337.91. Following the sale, the chief operating officer directly owned 2,170,877 shares in the company, valued at approximately $398,377,638.27. The trade was a 4.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, General Counsel Philip Mazzara sold 10,000 shares of the business's stock in a transaction dated Thursday, August 28th. The stock was sold at an average price of $188.70, for a total transaction of $1,887,000.00. Following the completion of the sale, the general counsel owned 161,573 shares in the company, valued at approximately $30,488,825.10. This trade represents a 5.83% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,832,489 shares of company stock valued at $264,172,396 in the last quarter. 12.50% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the stock. Jefferies Financial Group increased their target price on shares of Astera Labs from $95.00 to $130.00 and gave the stock a "buy" rating in a research report on Tuesday, July 22nd. Stifel Nicolaus set a $145.00 target price on shares of Astera Labs and gave the stock a "buy" rating in a research report on Monday, August 4th. William Blair assumed coverage on shares of Astera Labs in a research report on Thursday, May 22nd. They issued an "outperform" rating for the company. Northland Securities downgraded shares of Astera Labs from an "outperform" rating to a "market perform" rating and set a $120.00 price objective for the company. in a research report on Tuesday, July 22nd. Finally, Barclays reaffirmed an "overweight" rating and issued a $155.00 price objective (up previously from $75.00) on shares of Astera Labs in a research report on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $142.00.

Astera Labs Price Performance

Shares of ALAB opened at $232.90 on Friday. The business's fifty day moving average price is $152.34 and its 200 day moving average price is $102.63. Astera Labs, Inc. has a 12-month low of $40.78 and a 12-month high of $237.82. The stock has a market capitalization of $38.71 billion, a PE ratio of 415.89, a price-to-earnings-growth ratio of 5.84 and a beta of 1.48.

Astera Labs (NASDAQ:ALAB - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported $0.44 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.33 by $0.11. The company had revenue of $191.93 million for the quarter, compared to analysts' expectations of $172.46 million. Astera Labs had a return on equity of 9.53% and a net margin of 16.54%.The firm's quarterly revenue was up 149.5% compared to the same quarter last year. During the same period last year, the business posted $0.13 earnings per share. Astera Labs has set its Q3 2025 guidance at 0.380-0.390 EPS. As a group, research analysts anticipate that Astera Labs, Inc. will post 0.34 earnings per share for the current fiscal year.

Astera Labs Profile

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.